Skip to main content

Table 3 Sequence analysis of PDGFRA exons 12 and 18 from primary cervical cancer tumors and normal cervix samples.

From: Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer

SAMPLE EXON 12 EXON 18
  localization change position amino acid localization change position amino acid
CU-194 WT WT
CU-493 WT Exon C >T GTC>GTT ht Codon824 Val > Val
CU-693 WT WT
CU-794 WT Exon C >T GTC>GTT hm Codon 824 Val > Val
CU-1094 WT Exon C >T GTC>GTT ht Codon 824 Val > Val
CU-1194 WT Exon C >T GTC>GTT ht Codon 824 Val > Val
CU-1494 WT WT
CU-1593 WT Exon C >T GTC>GTT ht Codon 824 Val > Val
CU-2294 WT Exon C >T GTC>GTT ht Codon 824 Val > Val
CU-3194 WT Exon C >T GTC>GTT hm Codon 824 Val > Val
CU-3293 WT Exon C >T GTC>GTT ht Codon 824 Val > Val
CU-3994 WT Exon C >T GTC>GTT hm Codon 824 Val > Val
CU-4594 WT WT
CU-4793 WT WT
CU-4994 WT WT
CU-5393 WT WT
CU-5593 WT Exon C >T GTC>GTT ht Codon 824 Val > Val
CN-893 Intron C > A IVS12 +22 ------ Exon C >T GTC>GTT ht Codon 824 Val > Val
CN-993 Intron C > A IVS12 +22 ----- Exon C >T GTC>GTT ht Codon 824 Val > Val
CN-994 WT Exon C >T GTC>GTT ht Codon 824 Val > Val
HD WT WT
  1. WT: wild type; IVS: intronic variation sequence; ht: heterozygous; hm: homozygous. CU = cervical cancer, CN = non-neoplastic cervix, HD = healthy donor lymphocytes. The polymorphisms were presented as ht = heterozygous or hm = homozygous. [RefSeq accession D50017]. All patients were wild type in exon 12, and 10 out of 17 had the silent mutation C >T in codon 824 GTC>GTT, Val>Val [rs10015469]. 2 samples of non-neoplastic cervical tissue presented the intronic variation C>A IVS12+22 [rs2307051] and all 3 presented the silent mutation in codon 824 [rs10015469]. In this table we show the results of only one lymphocytes donor, but all 8 donors were wild type for exon 12, and 3 out of 8 presented the polymorphism at codon 824.